Financials
Financial year 2025
Worth noting
- Little cash and receivables against the short-term debts.
Revenue
€ 107 million
▲ 7% vs 2024
Profit
Growing€ 31,966
▲ 147% vs 2024
Debts
Normal€ 48.1 million
▲ 61% vs 2024
OMRIX BIOPHARMACEUTICALS from Machelen (Brab.), company number BE0455883073, closed financial year 2025 with a result of € 31,966 after tax. For that financial year OMRIX BIOPHARMACEUTICALS recorded revenue of € 107 million and equity of € 18.5 million. Compared with financial year 2024, the result moved from € 12,947 to € 31,966. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
What happened at OMRIX BIOPHARMACEUTICALS?
What happened at OMRIX BIOPHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Elena Gironi stepped down as director. NBB
- Wim Adriaenssens stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 31,966 (▲ 147% vs 2024). Source: NBB ↗
- Elena Gironi became a director. NBB
- Wim Adriaenssens became a director. NBB
- New establishment in Machelen (Brab.). KBO
- Start of the company according to the CBE. KBO
In short
From € 1.6 million profit in 2022 to € 31,966 profit in 2025.
Paid € 981,939 in corporate taxes since 2022.
Best year ever: 2022, with € 1.6 million profit.
Pays suppliers within 74 days on average.
A new publication or filing at OMRIX BIOPHARMACEUTICALS? We notify you, reason included.
Follow OMRIX BIOPHARMACEUTICALSNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Wim Adriaenssens
Director
since 2021 · until 2028
since 2023 · until 2029
Establishments
Establishment units
Physical locations of this company
Leonardo da Vincilaan 15
1831 Machelen (Brab.)
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
JOHNSON & JOHNSON MEDICAL
€ 330 million revenue · 2025
BELGIUM - LUXEMBOURG ORACLE USER GROUP
JJSV Belgium
€ 7.6 million revenue · 2024
GMED HEALTHCARE same network
€ 3,610.8 million revenue · 2025
DePuy Synthes (Belgium)
+1 more
Details
- Company number
- 0455.883.073
- VAT number
- BE 0455.883.073
- Registered office
- Leonardo da Vincilaan 15, 1831 Machelen (Brab.)
- Names & denominations
- OMRIX BIOPHARMACEUTICALS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 31 August 1995
- Peppol
- Active · Active since 18 Dec 2025
- Activities · NACE
Activiteiten van hoofdkantoren
Coördinatiecentra
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen